JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Immunocore Holdings PLC ADR

Gesloten

32.4 -0.64

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.2

Max

32.68

Belangrijke statistieken

By Trading Economics

Inkomsten

29M

5M

Verkoop

9.8M

94M

Winstmarge

5.35

Werknemers

493

EBITDA

13M

-3.6M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+106.36% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

131M

1.6B

Vorige openingsprijs

33.04

Vorige sluitingsprijs

32.4

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 23:11 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 aug 2025, 22:45 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 aug 2025, 22:39 UTC

Winsten

Great-West Lifeco Logs Lower 2Q Profit

5 aug 2025, 21:32 UTC

Winsten

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 aug 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 aug 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 aug 2025, 23:19 UTC

Marktinformatie

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 aug 2025, 23:03 UTC

Marktinformatie
Winsten

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 aug 2025, 22:22 UTC

Winsten

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 aug 2025, 22:21 UTC

Winsten

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 aug 2025, 22:20 UTC

Winsten

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 aug 2025, 22:18 UTC

Winsten

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 aug 2025, 22:15 UTC

Winsten

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 aug 2025, 21:58 UTC

Winsten

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 aug 2025, 21:30 UTC

Winsten

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 aug 2025, 21:26 UTC

Winsten

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 aug 2025, 21:23 UTC

Winsten

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 aug 2025, 21:17 UTC

Winsten

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

106.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 67.13 USD  106.36%

Hoogste 100 USD

Laagste 36 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.